FDA Approves Octaplas® Expanding Octapharma USA, Inc.'s Transfusion Medicine Therapies
1/18/2013 8:02:53 AM
More...
|
Octapharma AG Sponsors Educational Programs, Presents Research at the 64th Annual NHF Meeting in Orlando
11/7/2012 10:05:22 AM
More...
|
Octapharma AG Opens $32 Million Recombinant Research Facility in Heidelberg
9/28/2012 7:11:45 AM
More...
|
Octapharma AG Hosts Symposium at World Federation of Hemophilia World Congress on "Personalizing the Inhibitor Treatment and Prevention" in Hemophilia A
7/25/2012 10:15:36 AM
More...
|
Octapharma AG Hosts Symposium at WFH World Congress on Meeting the Challenges of Von Willebrand Disease (VWD) Diagnosis and Treatment
7/25/2012 9:35:44 AM
More...
|
Octapharma AG Releases 2011 Annual Report
4/3/2012 10:19:14 AM
More...
|
Octapharma AG Reports Octagam® 5% and Octagam® 10% Global Sales Totaled 1.7 Million Grams Through October With No Thromboembolic Events
11/15/2011 12:11:25 PM
More...
|
Octapharma AG Launches Clinical Trial to Evaluate Efficacy & Safety of Wilate(R) in Preventing Surgical Bleeding in Type 3 Von Willebrand Disease Patients
9/26/2011 12:20:37 PM
More...
|
Octapharma AG: European Commission Adopts European Medicines Agency's (EMA) Recommendation to Lift the Suspension of the Marketing Authorization of octagam(R) and octagam(R)10%
5/31/2011 9:58:49 AM
More...
|
Octapharma AG: European Medicines Evaluation Agency Recommends to Lift the Suspension of the Marketing Authorization of octagam(R)
4/15/2011 6:54:16 AM
More...
|
|